Özet:

In recent years in acute myocardial infarction, thrombolytic agents have been evaluated by many broad, randomized, control group studies and have been confirmed to significantly reduce mortality. No pharmacological initiative in AMI has ever changed the natural course of this disease so continuously and strongly. The trombolithic agents have been shown to resume the blood flow in the myocard, which is pre-ischemic, by solving the contagious coronary thrombus. Serious clinical studies have found that thrombolithic treatment relieves potential necrotic myocard, corrects residual left ventricular functions and, most importantly, reduces hospital mortality in patients with transmural myocard infarction. Since it only requires a peripheral intravenous pathway, this treatment can be applied early, at very different locations (accurate servicing, helicopter or home) and at a relatively low cost. The biggest international experience to date has accumulated on streptoquinase (SKZ) because its low-cost and mortality-reducing effect has been shown in many major studies. This study was still done to investigate the availability of the use of thrombolithic agents in the state hospitals in Turkey, where it is only limited to the cardiological centers. The study compared 17 cases, age, gender, birth pain, the distribution of risk factors and the distribution of infarction localizations with 13 people who had no statistically meaningful differences in terms of the "old group of patients" in January-April 1992. Frequent ventricular early outbreaks (class 4b and above according to Lown and Wolf a) (p<0.05); supraventricular cardio (p<0.05); bradikardi (p<0.0); branch and fasicular blocks (p<0.02); post-infarct angina (p<0.02) were statistically significantly less found. In the SKZ group, congestive heart failure was 11.7%, in the old group 23%, and mortality was 5.3%, respectively, but there was no statistical significance. In the SKZ group, 3 of the 3 patients who were present in the arrival branch and focicle block disappeared with block therapy. In the average 2 months, 5 of 5 patients with coronary angiography found an artery responsible for infarction openly. As a result, it has been observed that the treatment of streptoquinase, which is relatively cheap compared to similarities that have very positive effects on the early prognosis of AMI, is easy to use outside the cardiological centers in Turkey and is a reliable and necessary treatment regime.

Anahtar Kelimeler: